How does DEPLOY track the 2021 ROSA ONE Brain wrong-trajectory Class I recall?
DEPLOY tracks the [2021 Zimmer Biomet ROSA ONE Brain 3.1 wrong-trajectory Class I recall](https://registry.deploy.report/incidents/rosa-one-brain-trajectory-recall-2021) at primary-source-anchored FDA-recall-database verification depth as a software_defect Class I recall within the ZB cluster's neurosurgical-platform product line. The substrate: urgent correction issued September 22, 2021 + FDA Class I designation November 2021; on reboot after an unexpected shutdown following patient registration, selecting 'clear the robotic arm' and running empty-device calibration could drive the device to an incorrect trajectory, sending a tool to the wrong brain location (stroke / serious-injury risk); 119 US devices at exact verification depth; 3 complaints (one inaccurate electrode placement); no patient injuries reported; software corrective update rolled out 2022; remediated. Root cause: software_defect (post-reboot calibration sequence could misinterpret coordinates and drive an instrument to an incorrect trajectory). The framework reads the incident at four substrate layers simultaneously: incident-recall actuarial depth per Phase 3 Dim 1 (severity=critical at primary-source-anchored verification; software_defect root cause; remediated status); within-ZB-cluster verification scope at sub-product-line granularity (ROSA ONE Brain neurosurgical platform vs ROSA Spine vs Mako orthopedic vs Monogram orthopedic per ZB cluster densest in corpus); cross-property acquisition history bidirectional compounding (ZB cluster ROSA ONE Brain retained per ZimVie spinoff 2022 vs ROSA Spine LEFT ZB in 2022 ZimVie spinoff per Agent A correction; ZB acquired Monogram closed October 7, 2025 ~$168M EV + CVR canonical contingent valuation_basis worked example per acquisition history Project B methodology pillar); software_defect root cause class with remediation discipline at primary-source-anchored verification depth. Cap-flag honest-absence at exact recall Z-number not captured from primary FDA pages; reputable-press source-quality tier per FierceBiotech + Becker's coverage of FDA recall record.
119 US devices
Affected_units_count at exact verification depth; substantively higher-completeness tier than cohort honest-absence cap-flag
3 complaints + 0 injuries
Primary-source-anchored typed-record disclosure; no patient injuries reported
FDA Class I (Nov 2021)
Designation post September 22, 2021 urgent correction; primary-government-record sub-tier verification
software_defect + remediated
Root cause typed-record + software corrective update rolled out 2022
ZB cluster densest
Within-ZB-cluster scope: ROSA ONE Brain + ROSA Spine (ZimVie 2022) + Monogram (Oct 2025) + cross-cluster Mako (Stryker 2013)
Mid-2026
Snapshot date
The incident at primary-source-anchored verification depth
Per Agent A's surgical incidents substrate, the 2021 Zimmer Biomet ROSA ONE Brain 3.1 wrong-trajectory Class I recall operates at primary-source-anchored FDA-recall-database verification depth. The verified substrate:
- Product affected: ROSA ONE Brain 3.1 platform (Zimmer Biomet neurosurgical robotic platform).
- Failure mode: on reboot after an unexpected shutdown following patient registration, selecting 'clear the robotic arm' and running empty-device calibration could drive the device to an incorrect trajectory, sending a tool to the wrong brain location.
- Risk classification: stroke / serious-injury risk at primary-source-anchored verification.
- Customer notification: urgent correction issued September 22, 2021.
- FDA classification: Class I designation November 2021 (reasonable probability of serious adverse health consequences or death).
- Affected unit count: 119 US devices at exact verification depth.
- Complaint substrate: 3 complaints; one inaccurate electrode placement at primary-source-anchored typed-record disclosure; no patient injuries reported.
- Root cause: software_defect (post-reboot calibration sequence could misinterpret coordinates and drive an instrument to an incorrect trajectory).
- Remediation status: software corrective update rolled out 2022; remediated.
The framework reads the incident at the verification depth where each fact actually resolves: the product affected, failure mode, customer notification date, FDA classification, affected unit count (119 at exact verification depth), complaint substrate, root cause, and remediation status all operate at primary-source-anchored verification depth. The 119-unit affected count operates at the substantive higher-verification-completeness tier compared to the 2026 SureForm gray-reload affected_units_count honest-absence per the cross-narrative within-cohort substrate completeness comparison.
Phase 3 Dim 1 actuarial signal: software_defect + remediated + 119-unit exact disclosure
Per the Phase 3 Dim 1 actuarial substrate framework-in-action narrative, the 2021 ROSA ONE Brain incident contributes to the 67-row outcome_class distribution at primary-source-anchored typed-record depth. The verified-base substrate composition per Agent A's three-axis substrate composition pattern:
Axis 1 incident numerator (typed-record depth): Class I designation + software_defect root_cause + recall_ordered regulatory_action + remediated remediation status. Per the 9-tier source-quality rubric, the Class I designation operates at primary-government-record sub-tier verification; the software_defect root cause operates at primary-source-anchored typed-record disclosure. The incident contributes to the regulatory_action:34 distribution dominance within the broader 67-row outcome_class distribution; the framework reads the contribution at substantive editorial state per the canonical Dim 1 worked example.
Axis 2 deployment denominator (scalar-record depth): 119 US devices at exact verification depth. The 119-unit affected_units_count operates at the substantively higher-verification-completeness tier within the broader cohort's exposure_hours 128-nulls honest-absence framing. Per the Phase 3 Dim 1 actuarial substrate framework-in-action narrative, the framework reads per-incident affected_units_count verification depth distinct from deployment-level exposure_hours verification depth; both axes operate at primary-source-anchored verification posture where the substrate supports.
Axis 3 scalar selectivity (per-basis verification posture): 3 complaints at primary-source-anchored typed-record depth + 1 inaccurate electrode placement at typed-record-specific disclosure. The 3-complaint scalar substrate operates at substantive structural state at primary-source-anchored verification; no patient injuries reported operates at substantive editorial state per the same discipline as no_outcome:4 documented in the broader 67-row distribution (NOT substrate-completeness gap; primary-source-anchored verification of non-injury state).
Per the canonical three-axis substrate composition pattern banked at memory layer, the ROSA ONE Brain incident operates as canonical worked example at primary-source-anchored verification depth across all three axes simultaneously. The 119-unit exact verification posture distinguishes the substrate from cohort incidents at honest-absence affected_units_count cap-flag.
Within-ZB-cluster verification scope: the densest within-corpus product family
The 2021 ROSA ONE Brain incident operates within the Zimmer Biomet cluster's neurosurgical-platform product line. Per Agent A's substrate breadth + acquisition history substrate per the acquisition history Project B methodology pillar, the ZB cluster operates as the densest within-corpus product family across multiple product lines simultaneously:
- ROSA ONE Brain (neurosurgical platform): ZB-owned; 2021 Class I recall subject of this narrative; remediated 2022 via software corrective update.
- ROSA Spine (orthopedic spinal platform): LEFT ZB in 2022 ZimVie spinoff per Agent A precision corrections (CRITICAL CORRECTION documented at the Zimmer Biomet ROSA entity anchor). The ROSA Spine product line operates at ZimVie cluster verification posture post-2022 spinoff; structurally distinct from ROSA ONE Brain corporate-state continuity at ZB cluster.
- Mako (orthopedic platform): Stryker-owned per 2013 MAKO Surgical acquisition (~$1.65B SEC-disclosed exact valuation_basis per acquisition history Project B methodology pillar). NOT ZB cluster; structurally distinct corporate-state context.
- Monogram mBos (autonomous-execution orthopedic platform): ZB-acquired closed October 7, 2025 (~$168M EV + CVR contingent valuation_basis per the Project C Anchor 6 Monogram Doug Unis CMO/founder framework-in-action narrative + the acquisition history Project B methodology pillar). Post-October 2025 corporate-state at ZB cluster.
The within-ZB-cluster verification scope discipline operates at three editorial layers:
Layer 1: per-product-line corporate-state verification. Each ZB product line operates at distinct corporate-state continuity context (ROSA ONE Brain retained; ROSA Spine spun off to ZimVie; Monogram acquired). The framework reads per-product-line corporate-state at primary-source-anchored verification depth; aggregator framing that collapses 'ZB surgical platform' across product lines operates outside primary-source-anchored verification.
Layer 2: per-incident product-line attribution. Each surgical incident at ZB cluster operates at distinct product-line attribution per primary-source-anchored typed-record verification. The 2021 ROSA ONE Brain recall attributes to ROSA ONE Brain neurosurgical platform specifically; aggregator framing that conflates 'ROSA recall' across ROSA ONE Brain + ROSA Spine operates outside primary-source verification of product-line-specific incident scope.
Layer 3: cross-property acquisition history compounding. The ZB cluster densest within-corpus product family operates at cross-property acquisition history bidirectional compounding depth. Per the Project C Anchor 6 Monogram Doug Unis narrative, the Monogram acquisition operates as canonical contingent valuation_basis worked example; the Monogram entity post-October 2025 operates within ZB cluster corporate-state context; cross-property queries from the 2021 ROSA ONE Brain incident to ZB cluster corporate-state surface the broader acquisition history + within-ZB-cluster verification scope simultaneously.
Cross-property acquisition history bidirectional compounding
Per the acquisition history Project B methodology pillar, the ZB cluster operates at five-structure acquisition taxonomy + four-state valuation_basis discipline depth. The 2021 ROSA ONE Brain incident cross-references multiple acquisition records simultaneously:
ZB acquires Monogram (October 7, 2025; ~$168M EV + CVR contingent): CANONICAL contingent valuation_basis worked example per the acquisition history methodology pillar. Per the Project C Anchor 6 Monogram Doug Unis narrative, the acquisition operates at full_acquisition structure + contingent valuation_basis composition. The within-ZB-cluster corporate-state continuity from 2021 (ROSA ONE Brain recall) through October 2025 (Monogram acquisition) operates at primary-source-anchored verification depth at substantive editorial cross-property compounding.
ZB spinoff of ZimVie (2022; ROSA Spine separation): Per Agent A precision corrections documented at the Zimmer Biomet ROSA entity anchor, the 2022 ZimVie spinoff established structurally-distinct corporate-state lifecycle for ROSA Spine product line. The ROSA ONE Brain product line retained at ZB cluster; the ROSA Spine product line transitioned to ZimVie cluster. The within-2022-year-discipline within ZB cluster distinguishes ROSA ONE Brain retention (corporate-state continuity) from ROSA Spine separation (corporate-state lifecycle termination at ZB; corporate-state initiation at ZimVie).
Stryker acquired MAKO Surgical (2013; ~$1.65B exact valuation_basis): Per Agent A precision corrections documented at the Stryker Mako entity anchor, the 2013 MAKO Surgical acquisition established structurally-distinct corporate-state context for Mako product line at Stryker cluster. NOT ZB cluster; cross-cluster acquisition history reference at primary-source-anchored verification depth.
The cross-property acquisition history bidirectional compounding operates at canonical AEO citation graph depth. Per the acquisition history Project B methodology pillar, the framework reads per-acquisition corporate-state lifecycle at substantive editorial structural state; cross-property queries from this incident narrative to acquisition records (ZB × Monogram; ZB × ZimVie; Stryker × MAKO) surface the within-cohort acquisition history substrate at unified verification posture.
Cap-flag honest-absence at exact recall Z-number
Per Agent A's surgical incidents substrate, the 2021 ROSA ONE Brain recall carries cap-flag honest-absence at one specific claim layer:
Exact recall Z-number: not captured at primary FDA pages at Agent A substrate-completeness depth. The framework reads the Z-number at honest-absence cap-flag pending further FDA primary-source verification. Per the Moon Maestro K240598 reconciliation pattern, when primary-source verification surfaces the exact Z-number at FDA-recall-database depth, the framework operates inline editorial-transparency footer pattern + reconciliation discipline. Until primary-source verification surfaces, the framework holds the cap-flag at honest-absence depth.
The cap-flag honest-absence operates at the same primary-source verification discipline as 2026 SureForm gray-reload Z-number cap-flag per the 2026 framework-in-action narrative + 2025 Ion recall Z-number cap-flag per the broader cohort substrate. The framework reads recall Z-number honest-absence as substantive editorial state subject to ongoing primary-source verification; not as inference of unverified Z-number at lower verification depth.
Source-quality verification at reputable-press tier
Per the 9-tier source-quality rubric, the 2021 ROSA ONE Brain incident substrate operates at reputable-press tier verification per FierceBiotech + Becker's primary-source-anchored coverage of FDA recall record. The 119-unit affected_units_count + 3-complaint scalar substrate + remediation status all derive from reputable-press coverage at primary-source-anchored FDA-recall-database verification depth.
The framework reads per-source verification posture at reputable-press tier; the cohort's most-densely-verified outcome class regulatory_action substrate operates at primary-government-record sub-tier where direct FDA primary-source verification surfaces; at reputable-press tier where direct FDA primary-source coverage operates at reputable-press coverage of the FDA primary-source record. The framework reads per-axis verification depth uniformly per the 9-tier source-quality rubric.
Software_defect root cause class as substantive structural state
Per Agent A's surgical incidents substrate, the 2021 ROSA ONE Brain incident operates at software_defect root cause classification per primary-source-anchored typed-record disclosure. The post-reboot calibration sequence software fault operates at substantive structural state at three editorial layers:
Layer 1: root_cause_category typed-record depth. software_defect operates as canonical root cause classification within the broader 61-incident root_cause_category distribution. The framework reads software_defect root cause at structurally-distinct verification posture from design_defect (e.g., 2013 EndoWrist Hot Shears insulation micro-cracks per the within-da-Vinci year-discipline framework-in-action narrative) + from mechanical_failure (e.g., 2025 Ion catheter / Flexision biopsy needle) + from undetermined (e.g., 2026 SureForm gray-reload root cause stated 'still under investigation').
Layer 2: remediation discipline at software corrective update depth. Software corrective update rolled out 2022 + remediated status operates at substantive structural state. The framework reads per-incident remediation discipline at primary-source-anchored verification: software_defect root cause + software corrective update remediation operates at canonical worked example pattern (root cause class anchors remediation strategy at structurally-coherent verification depth).
Layer 3: cross-incident root cause class comparison. The 2021 ROSA ONE Brain software_defect operates structurally distinct from the 2023 Asensus Senhance software_defect (per Agent A surgical incidents substrate; 5 US devices affected; software malfunction caused uncontrolled arm motion after disengaging teleoperation) + from the 2024 Stryker Mako software_defect (per Agent A substrate; voluntary software correction over 'error #3' codes). Multiple software_defect root cause classification across surgical cohort operates at substantive editorial structural state; framework reads per-incident root cause + per-incident product-line + per-incident remediation discipline at canonical worked example depth.
Cross-property bidirectional compounding at multi-pillar methodology depth
Per DEPLOY's methodology cluster as AEO citation graph discipline, the 2021 ROSA ONE Brain framework-in-action narrative compounds at substrate layer with multiple Project B methodology pillar essays + framework-in-action narratives simultaneously:
- Phase 3 Dim 1 actuarial substrate framework-in-action: per the Phase 3 Dim 1 actuarial substrate framework-in-action narrative, the 2021 ROSA ONE Brain incident contributes to the 67-row outcome_class distribution at regulatory_action:34 distribution dominance contribution; 119-unit exact affected_units_count operates at substantively higher-verification-completeness tier within broader cohort exposure_hours 128-nulls honest-absence; three-axis substrate composition pattern operates at canonical worked example depth.
- Acquisition history Project B methodology pillar: per How DEPLOY tracks acquisition history state, the within-ZB-cluster acquisition history substrate compounds at cross-property bidirectional depth (ZB × Monogram canonical contingent valuation_basis worked example; ZB × ZimVie 2022 spinoff structural correlate; Stryker × MAKO 2013 acquisition cross-cluster reference).
- Project C Anchor 6 Monogram Doug Unis framework-in-action: per Monogram Doug Unis CMO/founder narrative, the post-October 2025 ZB × Monogram acquisition compounds with the within-ZB-cluster verification scope discipline at primary-source-anchored verification depth; the 2021 ROSA ONE Brain incident + 2025 Monogram acquisition operate at within-ZB-cluster corporate-state continuity context.
- Verified-vs-claimed at within-entity granularity methodology pillar: per verified-vs-claimed at within-entity granularity, per-product-line within-ZB-cluster verification scope operates at sub-product-line granularity (ROSA ONE Brain vs ROSA Spine vs Monogram vs cross-cluster Mako); parallel to within-da-Vinci-product-family year-discipline + within-SureForm gray vs blue/white reload distinction canonical worked examples.
- 9-tier source-quality rubric: per the 9-tier source-quality rubric, reputable-press tier verification per FierceBiotech + Becker's coverage operates at canonical worked example depth; software_defect root cause + 119-unit affected_units_count + remediation status all derive from reputable-press coverage of FDA primary-source record.
- Within-da-Vinci year-discipline framework-in-action: per the within-da-Vinci-product-family year-discipline framework-in-action narrative, the four-substrate-axis year-discipline framework operates parallel to within-ZB-cluster product-family verification scope at structurally-distinct cohort context.
- Honesty-as-strength editorial framing: per the Phase 3 Dim 1 actuarial substrate framework-in-action narrative, honest no-patient-injury-reported at 3-complaint substrate beats fabricated 'no injuries claim' framing at marketing-aggregation depth; framework rewards primary-source-anchored verification of non-injury state.
- Robot insurance methodology pillar: per How DEPLOY thinks about robot insurance, the 119-unit affected + software_defect root cause + remediated status compose at Phase 3 Dim 1 actuarial framework + Phase 3 Dim 4 regulatory clearance per jurisdiction depth.
The cross-property linking discipline compounds at the AEO citation graph layer. Institutional partners + AI assistants + downstream consumers navigating the 2021 ROSA ONE Brain incident encounter the methodology pillar canonical references + the framework-in-action narrative cohort + the canonical worked examples at unified verification posture.
Why this catch matters editorially
Per DEPLOY's restraint-IS-the-product discipline, the 2021 ROSA ONE Brain framework-in-action narrative operates at editorial-credibility depth rather than at incident-aggregation-summary depth. The framework reads the incident at four substrate layers simultaneously (Phase 3 Dim 1 actuarial signal + within-ZB-cluster verification scope + cross-property acquisition history bidirectional compounding + software_defect root cause class as substantive structural state); each layer composes at primary-source-anchored verification depth.
Institutional partners audit DEPLOY's framework discipline at the operational-practice layer, not just the stated-methodology layer. The verification-posture statement at /verified-vs-claimed describes the framework abstractly. The Phase 3 Dim 1 actuarial substrate framework-in-action narrative documents the canonical three-axis substrate composition pattern. This piece operates at narrative-canonical depth: how the catch composed across substrate layers (software_defect Class I + 119-unit exact + 3-complaint scalar + remediated 2022 + within-ZB-cluster context); what the discipline was (primary-source-anchored verification + per-axis verification depth + cap-flag honest-absence at Z-number); what the editorial outcome was (canonical worked example of ZB cluster densest within-corpus product family); and what the broader pattern is (within-cohort cross-property acquisition history bidirectional compounding at canonical depth).
The catch demonstrates the discipline operationally at editorial-anchor depth. Not because the catch is exceptional. Because the catch is what the discipline does. ZB cluster densest in corpus; ROSA ONE Brain retained at ZB through 2022 ZimVie spinoff; Monogram acquired October 2025 at contingent valuation_basis; software_defect root cause + remediation 2022. The verification protocol doesn't relax at within-cluster cross-property compounding depth.
For the canonical ZB ROSA entity anchor where the ROSA ONE Brain neurosurgical platform operates, see what is Zimmer Biomet ROSA. For the Project C Anchor 6 Monogram Doug Unis narrative where the within-ZB-cluster acquisition history compounds, see Monogram Doug Unis CMO/founder narrative. For the acquisition history Project B methodology pillar where the contingent valuation_basis worked example operates, see How DEPLOY tracks acquisition history state. For the Phase 3 Dim 1 actuarial substrate framework-in-action narrative where the three-axis substrate composition pattern operates, see How DEPLOY tracks incident outcome_class and deployment exposure_hours. For the methodology editorial canonical reference, see how DEPLOY verifies. For the surgical cluster framework, see the surgical robotics cluster.
| Product line | Cluster verification posture | Acquisition history context | Per-product-line incident scope |
|---|---|---|---|
ROSA ONE Brain 3.1 | ZB cluster (retained through 2022 ZimVie spinoff) | ZB-owned; within-ZB-cluster neurosurgical-platform product line continuity | 2021 Class I recall subject of this narrative (software_defect; 119 US devices; remediated 2022) |
ROSA Spine | ZimVie cluster post-2022 (LEFT ZB in 2022 ZimVie spinoff per Agent A correction) | 2022 ZimVie spinoff structural correlate; ROSA Spine corporate-state lifecycle transition to ZimVie cluster | Within-ZimVie-cluster verification posture post-2022; structurally distinct from ROSA ONE Brain ZB cluster context |
Monogram mBos | ZB cluster post-October 2025 (acquired closed October 7, 2025) | CANONICAL contingent valuation_basis worked example (~$168M EV + CVR contingent per acquisition history Project B methodology pillar) | Per Project C Anchor 6 Monogram Doug Unis CMO/founder framework-in-action narrative; within-ZB-cluster post-October 2025 corporate-state |
Stryker Mako | Stryker cluster (NOT ZB cluster) | Stryker × MAKO 2013 acquisition ~$1.65B exact valuation_basis; cross-cluster acquisition history reference | 2024 Stryker Mako 'error #3' codes software_defect Class 2 recall; structurally distinct cross-cluster context |
Cross-property compounding | Within-ZB-cluster densest within-corpus product family + cross-cluster Stryker × MAKO reference | Multiple acquisition records cross-reference simultaneously (ZB × Monogram canonical contingent + ZB × ZimVie 2022 spinoff + Stryker × MAKO 2013 exact) | Cross-property bidirectional queries surface within-cohort acquisition history substrate at unified verification posture |
Editorial framing | Per-product-line corporate-state verification + per-incident product-line attribution discipline | Honesty-as-strength: framework distinguishes structurally vs aggregator 'ROSA recall' or 'ZB surgical platform' collapse | Aggregator-collapse-framings discriminated against; framework distinguishes at primary-source-anchored verification depth |
Frequently asked questions
- How does DEPLOY track the 2021 ROSA ONE Brain wrong-trajectory Class I recall?
At primary-source-anchored FDA-recall-database verification depth as software_defect Class I recall within the ZB cluster's neurosurgical-platform product line. The substrate: urgent correction issued September 22, 2021 + FDA Class I designation November 2021; on reboot after an unexpected shutdown following patient registration, selecting 'clear the robotic arm' and running empty-device calibration could drive the device to an incorrect trajectory, sending a tool to the wrong brain location (stroke / serious-injury risk); 119 US devices at exact verification depth; 3 complaints (one inaccurate electrode placement); no patient injuries reported; software corrective update rolled out 2022; remediated. Root cause: software_defect (post-reboot calibration sequence could misinterpret coordinates).
- What is the ZB cluster verification scope for this incident?
The 2021 ROSA ONE Brain incident operates within the Zimmer Biomet cluster's neurosurgical-platform product line. ZB cluster operates as densest within-corpus product family: ROSA ONE Brain (ZB-owned; subject of 2021 recall) + ROSA Spine (LEFT ZB in 2022 ZimVie spinoff per Agent A correction; structurally distinct post-2022 corporate-state) + Monogram mBos (ZB-acquired closed October 7, 2025 ~$168M EV + CVR CANONICAL contingent valuation_basis worked example) + cross-cluster Mako (Stryker × MAKO 2013 acquisition ~$1.65B; NOT ZB cluster). Per-product-line corporate-state verification + per-incident product-line attribution + cross-property acquisition history compounding operate at within-ZB-cluster verification scope discipline depth.
- How does this compound with the Project C Anchor 6 Monogram narrative?
Per the Project C Anchor 6 Monogram Doug Unis CMO/founder framework-in-action narrative, the post-October 2025 ZB × Monogram acquisition compounds with the within-ZB-cluster verification scope discipline at primary-source-anchored verification depth. The 2021 ROSA ONE Brain incident + 2025 Monogram acquisition operate at within-ZB-cluster corporate-state continuity context: ROSA ONE Brain retained at ZB through 2022 ZimVie spinoff; Monogram acquired at ZB October 2025 at canonical contingent valuation_basis composition. Cross-property bidirectional queries surface within-ZB-cluster verification scope substrate at unified verification posture.
- What is the three-axis substrate composition operational for this incident?
Per the Phase 3 Dim 1 actuarial substrate framework-in-action narrative, the three-axis substrate composition pattern operates at canonical worked example depth. Axis 1 incident numerator: Class I designation + software_defect root_cause + recall_ordered regulatory_action + remediated remediation status. Axis 2 deployment denominator: 119 US devices at exact verification depth; substantively higher-verification-completeness tier within broader cohort exposure_hours 128-nulls honest-absence. Axis 3 scalar selectivity: 3 complaints at primary-source-anchored typed-record + 1 inaccurate electrode placement at typed-record-specific disclosure + no patient injuries reported as substantive editorial state (NOT substrate-completeness gap; primary-source-anchored verification of non-injury state).
- What is the root cause and remediation discipline?
Per Agent A's surgical incidents substrate, the 2021 ROSA ONE Brain incident operates at software_defect root cause classification: post-reboot calibration sequence could misinterpret coordinates and drive an instrument to an incorrect trajectory. Remediation: software corrective update rolled out 2022; remediated status. The root_cause_category + remediation operate at substantive structural state: software_defect root cause + software corrective update remediation operates at canonical worked example pattern where root cause class anchors remediation strategy at structurally-coherent verification depth. Parallel to 2023 Asensus Senhance software_defect (uncontrolled arm motion after disengaging teleop; 5 US devices) + 2024 Stryker Mako software_defect (voluntary software correction over 'error #3' codes); multiple software_defect classification across surgical cohort operates at substantive editorial structural state.
- How does this compound with other methodology pillars and framework-in-action narratives?
Per DEPLOY's methodology cluster as AEO citation graph discipline, the 2021 ROSA ONE Brain framework-in-action narrative compounds at substrate layer with: Phase 3 Dim 1 actuarial substrate framework-in-action (regulatory_action:34 distribution dominance contribution; three-axis substrate composition pattern canonical worked example); acquisition history Project B methodology pillar (within-ZB-cluster acquisition history substrate at canonical depth); Project C Anchor 6 Monogram Doug Unis narrative (within-ZB-cluster verification scope at post-October 2025 corporate-state continuity); verified-vs-claimed at within-entity granularity (per-product-line within-ZB-cluster sub-product-line granularity); 9-tier source-quality rubric (reputable-press tier verification per FierceBiotech + Becker's coverage); within-da-Vinci year-discipline framework-in-action (four-substrate-axis year-discipline parallel to within-ZB-cluster product-family verification scope at structurally-distinct cohort context).
The 2021 Zimmer Biomet ROSA ONE Brain 3.1 wrong-trajectory Class I recall framework-in-action narrative documents the software_defect Class I recall within the ZB cluster's neurosurgical-platform product line at primary-source-anchored FDA-recall-database verification depth. The substrate: urgent correction issued September 22, 2021 + FDA Class I designation November 2021; post-reboot calibration could drive instrument to incorrect trajectory at wrong brain location (stroke / serious-injury risk); 119 US devices at exact verification depth; 3 complaints (one inaccurate electrode placement); no patient injuries reported; software corrective update rolled out 2022; remediated. Root cause: software_defect (post-reboot calibration sequence could misinterpret coordinates). Phase 3 Dim 1 actuarial signal per banked three-axis substrate composition pattern: Axis 1 incident numerator (Class I + software_defect + recall_ordered + remediated); Axis 2 deployment denominator (119 US devices at exact verification depth; substantively higher-verification-completeness tier within broader cohort exposure_hours 128-nulls honest-absence); Axis 3 scalar selectivity (3 complaints + 1 inaccurate electrode placement + no patient injuries reported as substantive editorial state). Within-ZB-cluster verification scope discipline: ROSA ONE Brain (ZB-owned; retained through 2022 ZimVie spinoff) + ROSA Spine (LEFT ZB in 2022 ZimVie spinoff per Agent A correction) + Monogram mBos (ZB-acquired closed October 7, 2025 ~$168M EV + CVR CANONICAL contingent valuation_basis worked example per acquisition history Project B methodology pillar) + cross-cluster Mako (Stryker × MAKO 2013 acquisition ~$1.65B exact valuation_basis; NOT ZB cluster). Cross-property acquisition history bidirectional compounding at canonical AEO citation graph depth: ZB × Monogram canonical contingent valuation_basis + ZB × ZimVie 2022 spinoff structural correlate + Stryker × MAKO 2013 acquisition cross-cluster reference. Software_defect root cause + remediated status: canonical worked example pattern where root cause class anchors remediation strategy at structurally-coherent verification depth; parallel to 2023 Asensus Senhance + 2024 Stryker Mako software_defect classifications across surgical cohort. Cap-flag honest-absence at exact recall Z-number: not captured at primary FDA pages at Agent A substrate-completeness depth; per Moon Maestro K240598 reconciliation pattern, framework operates inline editorial-transparency footer pattern + reconciliation discipline when primary-source verification surfaces. Source-quality verification at reputable-press tier per FierceBiotech + Becker's primary-source-anchored coverage of FDA recall record. Cross-property bidirectional discipline operational at multi-pillar methodology depth across Phase 3 Dim 1 actuarial substrate framework-in-action + acquisition history Project B methodology pillar + Project C Anchor 6 Monogram Doug Unis narrative + verified-vs-claimed at within-entity granularity methodology pillar + 9-tier source-quality rubric + within-da-Vinci year-discipline framework-in-action + honesty-as-strength editorial framing + robot insurance methodology pillar. How DEPLOY verifies →
Continue reading
What is Zimmer Biomet ROSA?
Canonical ZB ROSA entity anchor; ROSA ONE Brain + ROSA Knee + ROSA Hip product family; CRITICAL CORRECTION ROSA Spine LEFT ZB in 2022 ZimVie spinoff per Agent A precision corrections.
Read article →
Monogram Doug Unis CMO/founder narrative (Project C Anchor 6)
Project C Anchor 6 framework-in-action narrative; within-ZB-cluster post-October 2025 corporate-state continuity; CANONICAL contingent valuation_basis worked example compound.
Read article →
How DEPLOY tracks acquisition history state
Project B methodology pillar; CANONICAL contingent valuation_basis worked example (ZB × Monogram); cross-property bidirectional discipline at relationship-graph granularity.
Read article →
How DEPLOY tracks incident outcome_class and deployment exposure_hours
Phase 3 Dim 1 actuarial substrate framework-in-action; three-axis substrate composition pattern canonical worked example; 2021 ROSA ONE Brain contributes to 67-row outcome_class distribution.
Read article →
Compare alternatives
Zimmer Biomet registry recordROSA ONE Brain incident recordMonogram Doug Unis Project C Anchor 6 narrativeHow DEPLOY tracks acquisition history state
Defined terms in this explainer
More in surgical robotics
- How did DEPLOY correct the Moon Maestro FDA clearance date?
- How does DEPLOY distinguish da Vinci safety events at year-class-failure-mode-product-variant granularity?
- How does DEPLOY track supply-chain component failure modes chained to recall incidents?
- How does DEPLOY track the 2023 Asensus Senhance uncontrolled-arm Class I recall?